Publications and Presentations

Glycomimetic Treatment of Geographic Atrophy from AMD: A Case Study

Tarek Hassan, MD

Breakthroughs in GA: Heralding the Glycomic Revolution

Michael J. Tolentino, MD

Sialic Acid Mimetic Microglial Sialic Acid-Binding Immunoglobulin-like Lectin Agonism: Potential to Restore Retinal Homeostasis and Regain Visual Function in Age-Related Macular Degeneration

Michael J. Tolentino, MD, Andrew J. Tolentino, BS, Elizabeth M. Tolentino, Anitha Krishnan, PhD, Mohamed Genead, MD

Pharmaceuticals - MDPI

PolySialic acid-nanoparticles inhibit macrophage mediated inflammation through Siglec agonism: a potential treatment for age related macular degeneration

Anitha Krishnan, PhD, Victor G. Sendra, PhD, Diyan Patel, MS, Amit Lad, PhD, Michelle K. Greene, PhD, Peter Smyth, PhD, Samantha A. Gallaher, Úna M. Herron, PhD, Christopher J. Scott, PhD, Mohamed Genead, MD, Michael J. Tolentino, MD

Frontiers in Immunology

Edited by: Bebhinn Treanor

Developing Immunomodulatory Sialic Acid Mimetic Nanoparticles Therapeutics Utilizing High Affinity Ligands

Michael J. Tolentino, MD

Using Nature’s Design but Better… Pioneering a New Wave of Therapeutics Using Glycoimmunology

Mohamed Genead, MD

Harness the Power of Glycobiology and Nanotechnology to Address Unmet Medical Need

Anitha Krishnan, PhD

SIGLECs the Main Self-Pattern Recognition Receptors of the Immune System. A Promising Target for Inflammatory Modulation

Andrew J. Tolentino, BS, Michael J. Tolentino, MD, Elizabeth M. Tolentino, Anitha Krishnan, PhD, Mohamed Genead, MD

American Journal of Biomedical Science & Research

Innovation in Treatment Modalities

Mohamed Genead, MD - Panelist

Glycoimmunology: The Next Generation Treatment Paradigm for Geographic Atrophy

Tarek Hassan, MD

Modulation of Macrophages and Complement Dysfunction in Nonexudative AMD Utilizing Novel Sialic-acid Coated Nanoparticles

Baruch D. Kuppermann, MD, PhD

Modulation of Macrophages and Complement Dysfunction in Geographic Atrophy From Macular Degeneration Utilizing Sialic-acid Coated Nanoparticles

David Chow, MD

Modulation of Macrophages and Complement Dysfunction in Nonexudative AMD Utilizing Novel Sialic-acid Coated Nanoparticles

Carl D. Regillo, MD, FACS, FASRS

Glycoimmune Therapy as a Novel Treatment Approach for Geographic Atrophy

Sophie J. Bakri, MD, MBA, Jeffrey S. Heier, MD, Arshad M. Khanani, MD, Ma, FASRS, Baruch D. Kuppermann, MD, PhD, Carl D. Regillo, MD, FACS, FASRS, Peter K. Kaiser, MD, FASRS

Navigating the Expanding Availability of Retinal Imaging Technologies to Transform your Clinical Pipeline

David Callanan, MD

Modulation of Macrophages and Complement Dysfunction in Nonexudative Age-Related Macular Degeneration Utilizing a Sialic-acid Coated Nanoparticle.

Baruch D. Kuppermann, MD, PhD, David Callanan, MD, Tarek Hassan, MD, Michael J. Tolentino, MD, Christopher J. Scott, PhD, Mohamed Genead, MD, Anitha Krishnan, PhD

Modulation of Retinal Inflammatory Macrophages by Polysialic-Acid Coated Nanoparticles as Novel Mechanism for Nonexudative AMD Treatment.

Anitha Krishnan, PhD, , Victor G. Sendra, PhD, Amit Lad, PhD, David Callanan, MD, Tarek Hassan, MD, Michael J. Tolentino, MD, Christopher J. Scott, PhD, Mohamed Genead, MD

Targeting Self-Recognition Pattern Receptors on Retina Immune Cells with an Engineered Glycan-coated Nanoparticle as a Novel Therapy for Nonexudative AMD.

, Amit Lad, PhD, David Callanan, MD, Tarek Hassan, MD, Michael J. Tolentino, MD, Christopher J. Scott, PhD, Mohamed Genead, MD, Anitha Krishnan, PhD

Glycoimmunology: The Next Generation Treatment Paradigm for Geographic Atrophy

Tarek Hassan, MD

Glyco-Immunology: Attacking Dry AMD in a Different Way…

Tarek Hassan, MD

Glyco-Immunology in the Treatment of Dry AMD: Modulation of Innate Immunity with Novel Nano-Technology.

Robert Avery MD

Glyco-Immunology in the Treatment of Dry AMD: Modulation of Innate Immunity with Novel Nano-Technology.

Tarek Hassan, MD

New Wave of Glyco-Immuno Therapeutics Focus on Ophthalmology.

David Callanan, MD

Investigational drugs in clinical trials for macular degeneration

Michael J. Tolentino, MD, Andrew J. Tolentino, BS

1067-1085, DOI: 10.1080/13543784.2022.2113375

Modulation of Innate Immunity & Complement Dysfunction in Patients with Geographic Atrophy Utilizing a Novel Glyco-Engineered Therapeutic Nano-Technology.

Michael Singer, MD

Glyco-Engineered Coated Nanoparticles A Novel Therapeutic for the treatment of Dry AMD.

Michael J. Tolentino, MD

Modulation of Innate Immune & Complement Dysfunction in patients with Geographic Atrophy utilizing a novel glyco-engineered therapeutic nano-technology.

Peter K. Kaiser, MD, FASRS, David Callanan, MD, Michael J. Tolentino, MD, Derek Kunimoto, MD, Mohamed Genead, MD, Anitha Krishnan, PhD

Anti-inflammatory role of a glycan-coated nanoparticle in modulating macrophages and complement in non-exudative AMD.

Anitha Krishnan, PhD; Rajesh Shinde, PhD; Derek Kunimoto, MD; Michael J. Tolentino, MD; Mohamed Genead, MD

Targeting Innate Immune Activity in Age-Related Macular Degeneration Promising candidate molecules are in later stages of development.

Carl D. Regillo, MD, FACS, FASRS; Jeffrey S. Heier, MD

Retinal Physician, Volume: 18, Issue: April 2021, page(s): 42-45